Search results
Results From The WOW.Com Content Network
BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its ...
In this article we will take a look at whether hedge funds think BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a good investment right now. We check hedge fund and billionaire investor sentiment ...
List of largest biomedical companies by market capitalization. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) with current market capitalization of at least US$10 billion, ranked by their market capitalization. It does not include biotechnology companies that ...
For premium support please call: 800-290-4726 more ways to reach us
Show comments. (Reuters) -The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for severe hemophilia A, the company said, giving patients with the ...
(Reuters) - BioMarin Pharmaceutical said on Tuesday it will price its therapy for severe hemophilia A at 28,933.53 euros ($31,725.62) per vial for insurers covering a majority of the population in ...
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. The company is developing medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA ...
Overall, an acquisition of BioMarin would have to come at a premium to today's price to satisfy shareholders, and that means the acquirer wouldn't get much in terms of immediate cost savings.